Cytogenetics in the management of chronic lymphocytic leukemia: Guidelines from the Groupe Francophone de Cytogénétique Hématologique (GFCH)

Curr Res Transl Med. 2023 Oct-Dec;71(4):103410. doi: 10.1016/j.retram.2023.103410. Epub 2023 Sep 17.

Abstract

Chromosomal abnormalities are frequent in chronic lymphocytic leukemia (CLL), and most have prognostic value. In addition to the four well-known abnormalities (13q, 11q and 17p deletions, and trisomy 12), other recurrent aberrations have been linked to the disease outcome and/or drug resistance. Moreover, the complex karyotype has recently emerged as a prognostic marker for patients undergoing immunochemotherapy or targeted therapies. Here, we describe the main chromosomal abnormalities identified in CLL and related disorders (small lymphocytic lymphoma and monoclonal B-cell lymphocytosis) by reviewing the most recent literature and discussing their detection and clinical impact. Lastly, we provide technical guidelines and a strategy for the cytogenetic assessment of CLL.

Keywords: 17p deletion; 2p gain; 8p deletion; Chromosomal abnormalities; Chronic lymphocytic leukemia; MYC aberrations; TP53; complex karyotype.

Publication types

  • Practice Guideline

MeSH terms

  • Chromosome Aberrations
  • Cytogenetic Analysis
  • Humans
  • Leukemia, Lymphocytic, Chronic, B-Cell* / diagnosis
  • Leukemia, Lymphocytic, Chronic, B-Cell* / genetics
  • Leukemia, Lymphocytic, Chronic, B-Cell* / therapy
  • Prognosis